Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ultragenyx Pharmaceutical (RARE) Return on Assets: 2017-2025

Historic Return on Assets for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Sep 2025 value amounting to -0.47%.

  • Ultragenyx Pharmaceutical's Return on Assets fell 11.00% to -0.47% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.47%, marking a year-over-year decrease of 11.00%. This contributed to the annual value of -0.38% for FY2024, which is 2.00% up from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Return on Assets is -0.47%, which was down 14.07% from -0.41% recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Return on Assets' 5-year high stood at -0.12% during Q1 2021, with a 5-year trough of -0.54% in Q2 2023.
  • Moreover, its 3-year median value for Return on Assets was -0.44% (2024), whereas its average is -0.44%.
  • In the last 5 years, Ultragenyx Pharmaceutical's Return on Assets increased by 24bps in 2021 and then declined by 22bps in 2022.
  • Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Return on Assets stood at -0.30% in 2021, then declined by 15bps to -0.45% in 2022, then remained steady at -0.44% in 2023, then climbed by 7bps to -0.38% in 2024, then dropped by 11bps to -0.47% in 2025.
  • Its Return on Assets stands at -0.47% for Q3 2025, versus -0.41% for Q2 2025 and -0.39% for Q1 2025.